Plasminogen Activator Inhibitor 1 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)- Pipeline Review, H2 2019’, provides in depth analysis on Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Cardiovascular, Oncology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Respiratory, Immunology, Genetic Disorders, Metabolic Disorders and Undisclosed under development targeting Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)

– The report reviews Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Accendatech Au Pty Ltd

Beam Therapeutics Inc

Jazz Pharmaceuticals Plc

MDI Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Overview

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Companies Involved in Therapeutics Development

CisThera Inc

Jazz Pharmaceuticals Plc

MDI Therapeutics Inc

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Drug Profiles

Bispecific Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-140 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

defibrotide sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SK-216 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PAI1 for Immunology, Respiratory and Cardiovascular Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5275 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5441 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5484 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5614 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Dormant Products

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Discontinued Products

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Product Development Milestones

Featured News & Press Releases

Feb 23, 2018: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease

Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Defitelio at ASH 2017 Annual Meeting

Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients

Nov 07, 2016: Jazz Pharmaceuticals to Present New Data on Defitelio at the Annual ASH Meeting

Aug 02, 2016: CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation

Mar 30, 2016: FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow

Mar 30, 2016: Jazz Pharmaceuticals Announces Webcast for Defitelio (defibrotide sodium) Investor Update

Feb 18, 2016: Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting

Feb 01, 2016: Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD

Sep 30, 2015: Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease

Feb 12, 2015: Jazz Pharmaceuticals to Present Data on Defibrotide, an Investigational Treatment, in Patients with Hepatic Veno-Occlusive Disease at BMT Tandem Meetings

Dec 11, 2014: Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease

Dec 02, 2014: Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At ASH Annual Meeting

Mar 31, 2014: Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease

Dec 11, 2013: Interim Results From Gentium's Treatment IND for Defibrotide and Additional Data on Defibrotide in the Prevention of Acute Graft Versus Host Disease Presented at the American Society of Hematology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Accendatech Au Pty Ltd, H2 2019

Pipeline by Beam Therapeutics Inc, H2 2019

Pipeline by Jazz Pharmaceuticals Plc, H2 2019

Pipeline by MDI Therapeutics Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports